Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

被引:25
作者
Ge, Mengyuan [1 ,2 ]
Molina, Judith [1 ,2 ]
Kim, Jin-Ju [1 ,2 ]
Mallela, Shamroop K. [1 ,2 ]
Ahmad, Anis [3 ]
Varona Santos, Javier [1 ,2 ]
Al-Ali, Hassan [1 ,2 ]
Mitrofanova, Alla [1 ,2 ]
Sharma, Kumar [4 ]
Fontanesi, Flavia [5 ]
Merscher, Sandra [1 ,2 ]
Fornoni, Alessia [1 ,2 ]
机构
[1] Univ Miami, Dept Med, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA
[2] Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA
[3] Univ Miami, Dept Radiat Oncol, Miller Sch Med, Miami, FL USA
[4] Univ Texas Hlth San Antonio, Ctr Precis Med, Sch Med, San Antonio, TX USA
[5] Univ Miami, Dept Biochem & Mol Biol, Miami, FL USA
来源
ELIFE | 2023年 / 12卷
基金
美国国家卫生研究院;
关键词
Alport syndrome; lipid; energy substrate; SGLT2; inhibitor; Mouse; COTRANSPORTER; 2; INHIBITION; FATTY-ACID OXIDATION; DIABETIC KIDNEY; CELL-LINES; SGLT2; METABOLISM; EXPRESSION; MUTATIONS; APOPTOSIS; DISEASE;
D O I
10.7554/eLife.83353
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonstrate that SGLT2i affects energy metabolism and podocyte lipotoxicity in experimental Alport syndrome (AS). In vitro, we found that the SGLT2 protein was expressed in human and mouse podocytes to a similar extent in tubular cells. Newly established immortalized podocytes from Col4a3 knockout mice (AS podocytes) accumulate lipid droplets along with increased apoptosis when compared to wild-type podocytes. Treatment with SGLT2i empagliflozin reduces lipid droplet accumulation and apoptosis in AS podocytes. Empagliflozin inhibits the utilization of glucose/pyruvate as a metabolic substrate in AS podocytes but not in AS tubular cells. In vivo, we demonstrate that empagliflozin reduces albuminuria and prolongs the survival of AS mice. Empagliflozin-treated AS mice show decreased serum blood urea nitrogen and creatinine levels in association with reduced triglyceride and cholesterol ester content in kidney cortices when compared to AS mice. Lipid accumulation in kidney cortices correlates with a decline in renal function. In summary, empagliflozin reduces podocyte lipotoxicity and improves kidney function in experimental AS in association with the energy substrates switch from glucose to fatty acids in podocytes.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Combined Alport syndrome and Klinefelter syndrome
    Nishida, Masashi
    Hashimoto, Fusako
    Kaito, Hiroshi
    Nozu, Kandai
    Iijima, Kazumoto
    Asada, Dai
    Hamaoka, Kenji
    PEDIATRICS INTERNATIONAL, 2016, 58 (02) : 152 - 155
  • [22] Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative
    Kashtan, Clifford E.
    Ding, Jie
    Gregory, Martin
    Gross, Oliver
    Heidet, Laurence
    Knebelmann, Bertrand
    Rheault, Michelle
    Licht, Christoph
    PEDIATRIC NEPHROLOGY, 2013, 28 (01) : 5 - 11
  • [23] Alport syndrome and Alport kidney diseases - elucidating the disease spectrum
    Puapatanakul, Pongpratch
    Miner, Jeffrey H.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2024, 33 (03) : 283 - 290
  • [24] Genetic diagnosis of Alport syndrome in 16 Chinese families
    Xiao, Tangli
    Zhang, Jun
    Liu, Li
    Zhang, Bo
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2024, 12 (03):
  • [25] The importance of clinician, patient and researcher collaborations in Alport syndrome
    Rheault, Michelle N.
    Savige, Judith
    Randles, Michael J.
    Weinstock, Andre
    Stepney, Melissa
    Turner, A. Neil
    Parziale, Gina
    Gross, Oliver
    Flinter, Frances A.
    Miner, Jeffrey H.
    Lagas, Sharon
    Gear, Susie
    Lennon, Rachel
    PEDIATRIC NEPHROLOGY, 2020, 35 (05) : 733 - 742
  • [26] Ocular manifestations of Alport syndrome
    Xu, Jian-Min
    Zhang, Shi-Sheng
    Zhang, Qiong
    Zhou, Ying-Ming
    Zhu, Cai-Hong
    Ge, Jian
    Wang, Ling
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2010, 3 (02) : 149 - 151
  • [27] The Renal Lesions of Alport Syndrome
    Heidet, Laurence
    Gubler, Marie-Claire
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (06): : 1210 - 1215
  • [28] Corneal Clouding in Alport Syndrome
    Herwig, Martina C.
    Eter, Nicole
    Holz, Frank G.
    Loeffler, Karin U.
    CORNEA, 2011, 30 (03) : 367 - 370
  • [29] Alport Syndrome With Kidney Cysts Is Still Alport Syndrome
    Savige, Judy
    Mack, Heather
    Thomas, Rose
    Langsford, David
    Pianta, Tim
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (02): : 339 - 342
  • [30] Alport syndrome
    Karki, P.
    Shrestha, J. K.
    NEPALESE JOURNAL OF OPHTHALMOLOGY, 2009, 1 (02) : 139 - 140